Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of $1.60, $1.46 better than the analyst estimate of $0.14. Revenue for the quarter came in at $284 million versus the consensus estimate of $293.78 million.

GUIDANCE:

Acadia Pharma sees FY2026 revenue of $1.22-1.28 billion, versus the consensus of $1.2 billion.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.